CIRB Studies

Below is the current list of studies covered by the CIRB. Participants should refer to ClinicalTrials.gov for general information about clinical trials. Institutions should refer to the Clinical Trials Support Unit (CTSU) website  for enrollment requirements and accrual status information. 

Study documents approved after July 1, 2013 are available to participating institutions for covered studies on the CTSU website. To request documents approved before July 1, 2013, participating institutions can contact the CIRB Helpdesk.

Review CIRB
Study Number Network Study Title CIRB
B-31 dbGAP NSABP Comparison of methods for development of predictive signatures for therapy selection Adult CIRB - Late Phase Emphasis
C80405 CALGB A Phase III Trial of Irinotecan/5-FU/Leucovorin or Oxaliplatin/5-FU/Leucovorin with Bevacizumab; or Cetuximab (C225); or with the Combination of Bevacizumab and Cetuximab for Patients with Untreated Metastatic Adenocarcinoma of the Colon or Rectum Adult CIRB - Late Phase Emphasis
CALGB-100104 CALGB A Phase III Randomized; Double-Blind Study of Maintenance Therapy with CC-5013 (NSC #703813; IND#70116) or Placebo Following Autologous Stem Cell Transplantation for Multiple Myeloma Adult CIRB - Late Phase Emphasis
CALGB-10201 CALGB A Phase III Study of Daunorubicin and Cytarabine +\- G3139 (GenasenseTM; Oblimersen Sodium; NSC #683428; IND #58842); A BCL2 Antisense Oligodeoxynucleotide; in Previously Untreated Patients with Acute Myeloid Leukemia (AML) > 60 Years Adult CIRB - Late Phase Emphasis
CALGB-10501 CALGB A Phase III Intergroup CLL Study of Asymptomatic Patients with Untreated Chronic Lymphocytic Leukemia Randomized to Early Intervention Versus Observation with Later Treatment in the High Risk Genetic Subset with IgVh Unmutated Disease <br> Adult CIRB - Late Phase Emphasis
CALGB-10603 CALGB A Phase III Randomized; Double-Blind Study of Induction (Daunorubicin/Cytarabine) and Consolidation (High-Dose Cytarabine) Chemotherapy + Midostaurin (PKC412) (IND #101261) or Placebo in Newly Diagnosed Patients < 60 Years of Age with FLT3 Mutated Acute Myeloid Leukemia (AML) Adult CIRB - Late Phase Emphasis
CALGB-10701 CALGB A Phase II Study of Dasatinib (Sprycel) (IND #73969; NSC #732517) as Primary Therapy Followed by Transplantation for Adults >/= 18 Years with Newly Diagnosed Ph+ Acute Lymphoblastic Leukemia by CALGB; ECOG and SWOG Adult CIRB - Late Phase Emphasis
CALGB-140503 CALGB A Phase III Randomized Trial of Lobectomy versus Sublobar Resection for Small (= 2 Cm) Peripheral Non-Small Cell Lung Cancer Adult CIRB - Late Phase Emphasis
CALGB-30102 CALGB Phase III Comparison of Catheter Based Therapy of Pleural Effusions in Cancer Patients (Optimal Pleural Effusion Control; OPEC Adult CIRB - Late Phase Emphasis
CALGB-30506 CALGB A Randomized Phase III Trial of Adjuvant Chemotherapy in Patients with Early Stage Non-Small Cell Lung Cancer Associated with Banking of Frozen Tumor Specimens and Collection of Gene Expression Profile Data Adult CIRB - Late Phase Emphasis